AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 191 min read$MCK

McKesson Corp (MCK) EVP, CIO and CTO Francisco Fraga Sells 800 S

McKesson Corp (MCK) EVP Francisco Fraga sold 800 shares at $995.8 each, totaling $796,640. He now owns 5,423.496 shares. Over the past year, MCK insiders sold 18 times with no buys. MCK trades at a P/E of 27.04, above industry and historical medians, and is modestly overvalued per GF Value.

Original reporting
gurufocus.com
Published Oct 19, 2026, 10:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 4:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$MCK
Neutral
medium confidence
Mentioned
$MCK
Relevance
4/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

The disclosed sale is small relative to the insider's holdings and does not indicate a shift in company fundamentals.

02

Market read

Routine insider sell with limited trading relevance.

03

What to watch

No recent earnings surprise or strategic change accompanies the sale.

Relevance 4/10Novelty 3/10Timing: post-market filing

Background

McKesson is a large U.S. healthcare distributor with a market cap over $100B. Insider activity is often monitored by investors.

Company-level read

Ticker impact

$MCKNeutralMedium confidence
Context

SEC Form 4 disclosed that McKesson EVP CIO/CTO Francisco Fraga sold 800 shares at $995.8 each, a modest $0.8M sale.

Expected impact

likely slight pressure as market prices in the insider sell

Evidence & confidence

The sale represents less than 1% of the insider's remaining stake and is not material to valuation.

Market effects

Sector

Minimal; insider activity does not materially affect the healthcare distribution sector.

Regional

None; the filing is company‑specific.

Global

None

Counterpoint

What could challenge this read

The sale could be a routine diversification move, not a bearish signal.

Key entities

  • Executive
    Francisco Fraga

    McKesson EVP, CIO and CTO who sold 800 shares.

  • Company
    McKesson Corp

    Healthcare services and distribution company.

Read at source← All news

Related articles

OCT 27
$MCKLow

Built and Bred

McKesson (MCK) will invest $179M in a 330,000 sq. ft. regional distribution center in Moore, Oklahoma, creating 200+ jobs. The site's location, readiness, and regional coordination influenced the decision, according to the company.

citylifestyle.com2 min
OCT 10
$OPCHHighAI 9/10

Option Care Health Sold for $5.8B in CD&R-McKesson Deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson (MCK) for $5.8B, or $32.05 per share, a 37% premium. The deal, expected to close in 2027, values the company at $5.8B. Option Care Health will operate independently post-acquisition. The company reported $5.6B in 2025 revenue and $207.6M in net income, with modest growth in 2026. The acquisition aligns with McKesson's strategy to expand access to innovative therapies.

hoodline.com2 min
OCT 9
$MCKHighAI 9/10

McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?

McKesson (MCK) is acquiring Option Care Health (OPCH) for $5.8B, including debt, at $32.05 per share, a 37% premium. McKesson and private equity firm CD&R will own 49% and 51% respectively. The deal expands McKesson's specialty healthcare services. McKesson's Q1 2027 revenue was $105.4B, beating estimates, with adjusted EPS up 20% YoY to $9.93. The company raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00.

finance.yahoo.com2 min
OCT 8
$MCKHighAI 9/10

McKesson & CD&R Acquire Leading US Home-Infusion Platform

McKesson and private equity firm CD&R will acquire Option Care Health, a US home-infusion care provider, for $5.8bn. CD&R will take a majority stake, while McKesson invests $1.4bn for a minority stake. The deal values Option Care Health at $32.05 per share and is expected to close in H1 2027. McKesson aims to leverage the acquisition to expand its specialty care offerings.

healthcare-digital.com3 min
OCT 7
$OPCHHighAI 9/10

Option Care stock surges on McKesson's home-infusion bet

Option Care Health (OPCH) shares rose 33% to $31.11 after McKesson (MCK) and Clayton, Dubilier & Rice agreed to take it private for $32.05 per share, valuing it at $5.8B. McKesson will initially own 49%, with an option to acquire the rest later. The deal gives McKesson access to Option Care's home-infusion network, serving 315K+ patients. Option Care's Q2 revenue grew 1.9% to $1.44B. The deal needs shareholder and regulatory approvals to close in early 2027.

finance.yahoo.com2 min